Patient-derived malignant pleural mesothelioma cell cultures: a tool to advance biomarker-driven treatments

Thorax. 2020 Nov;75(11):1004-1008. doi: 10.1136/thoraxjnl-2020-215027. Epub 2020 Sep 17.

Abstract

Malignant pleural mesothelioma (MPM) is an aggressive cancer, associated with poor prognosis. We assessed the feasibility of patient-derived cell cultures to serve as an ex vivo model of MPM. Patient-derived MPM cell cultures (n=16) exhibited stemness features and reflected intratumour and interpatient heterogeneity. A subset of the cells were subjected to high-throughput drug screening and coculture assays with cancer-specific cytotoxic T cells and showed diverse responses. Some of the biphasic MPM cells were capable of processing and presenting the neoantigen SSX-2 endogenously. In conclusion, patient-derived MPM cell cultures are a promising and faithful ex vivo model of MPM.

Keywords: mesothelioma; pleural disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor / analysis*
  • Cell Culture Techniques
  • Genes, Tumor Suppressor
  • High-Throughput Screening Assays
  • Humans
  • Immunotherapy
  • Mesothelioma, Malignant / pathology*
  • Mesothelioma, Malignant / therapy
  • Mutation
  • Pleural Neoplasms / pathology*
  • Pleural Neoplasms / therapy
  • Tumor Cells, Cultured / cytology*
  • Whole Genome Sequencing

Substances

  • Biomarkers, Tumor